Ernexa Stock Price, News & Analysis

Eterna Therapeutics (ERNA) has expanded its scientific advisory board with the addition of two experts: Dr. Jerome Zeldis and Dr. Blythe Sather. Dr. Zeldis brings extensive experience in oncology therapy development, having served as Celgene's Chief Medical Officer and held leadership positions at various pharmaceutical companies. He has published 122 peer-reviewed articles and holds 44 U.S. patents.

Dr. Sather, an immunologist specializing in genetic and epigenetic modifications, brings expertise in cell therapy and genetic medicines. Her experience includes work with CRISPR gene editing, CAR-T cell therapies, and leadership roles at companies like Juno Therapeutics and Celgene.

Both advisors will contribute to advancing ERNA-101 for solid tumors and ERNA-102 for autoimmune diseases through preclinical studies.

Eterna Therapeutics (ERNA) announced positive preclinical study results for its lead cell therapy product, ERNA-101, targeting ovarian cancer. The proof-of-concept study demonstrated significant T cell infiltration after a single dose, reduced tumor burden, and extended survival in mouse models.

ERNA-101 successfully transformed 'cold' tumors into 'hot' ones by utilizing induced pluripotent stem cells to create mesenchymal stem cells that secrete interleukins IL-7 and IL-15. The therapy showed ability to enhance immune system response against tumors while limiting systemic exposure and potential toxicity.

In the study conducted at MD Anderson Cancer Center, researchers developed an ovarian tumor model using ID8 cells. The ERNA-101 treatment group showed substantially higher T cell infiltration, reduced tumor size, and significant survival advantage compared to control groups, with no significant differences in body weight distribution indicating favorable safety profile.

Eterna Therapeutics (NASDAQ: ERNA) has appointed Dr. Elena Ratner to its Board of Directors. Dr. Ratner, a Professor at Yale University School of Medicine's Department of Obstetrics, Gynecology, and Reproductive Sciences, will guide Eterna's strategic direction in combating ovarian cancer.

This appointment follows Eterna's recent collaboration with MD Anderson Cancer Center, focusing on developing novel therapies for ovarian and breast cancers. The company's lead candidate, ERNA-101, is a cell therapy designed to enhance immune system response against tumors by improving immune cell infiltration and activation.

Dr. Ratner currently serves as Director of the Discovery to Cure Early Ovarian Cancer Detection program and has received notable recognitions including the 2024 David and Cindy Leffell Clinical Excellence Award. Her research focuses on developing targeted drugs for ovarian cancer and addressing chemotherapy resistance in ovarian and uterine cancers.

Eterna Therapeutics (ERNA) has announced a research initiative to study ERNA-101, its lead induced mesenchymal stem cell therapy candidate, in ovarian and breast cancer models through a collaboration with MD Anderson Cancer Center. The research will examine ERNA-101's ability to induce and modulate antitumor immunity. ERNA-101 is an allogenic cell therapy derived from iPSCs that secretes IL-7 and IL-15. Based on the results, future studies may evaluate combinations with CAR T or CAR NK cell therapies in solid tumors. The project aims to generate data supporting ERNA-101's IND submission.

Eterna Therapeutics (Nasdaq: ERNA) has announced a stock repurchase program of up to $1 million of its outstanding common stock. The Board of Directors-authorized program allows repurchases through open market transactions, privately negotiated transactions, or other means in compliance with securities laws. The company's management will determine the timing and amount of repurchases based on market conditions, stock price, and other factors. The program has no set expiration date and can be suspended, modified, or discontinued at any time.

Eterna Therapeutics (Nasdaq: ERNA) has regained compliance with Nasdaq's continued listing requirements after meeting the market value standard of at least $35 million. The company received formal confirmation on November 12th, 2024, from Nasdaq's Office of General Counsel. Eterna is now positioned as a debt-free, low burn rate, preclinical stage cell therapy company focused on developing ERNA-101 for triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer treatments.

Eterna Therapeutics (NASDAQ: ERNA) has completed a comprehensive financial restructuring to accelerate its developmental activities. The restructuring includes: discontinuing a longstanding lease, resulting in $72 million in savings and reducing monthly cash outflow by $700,000; reducing balance sheet debt; and securing $5 million in PIPE financing.

The company continues advancing ERNA-101, an iPSC-derived mesenchymal stem cells product targeting triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer. Eterna targets IND submissions by 2026.

Eterna Therapeutics Inc. (Nasdaq: ERNA) and Factor Bioscience have announced an exclusive license and collaboration agreement to accelerate the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Eterna has secured a worldwide, exclusive license to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products using Factor's technologies.

The agreement focuses on iPSC-derived mesenchymal stem cells (iMSC) engineered to express specific cytokines. Eterna and Factor will collaborate on data generation to demonstrate efficacy of the licensed drug candidates for development towards IND. Factor is entitled to milestone payments per product candidate and post-commercialization royalties.

This collaboration aims to accelerate the development of therapies targeting solid tumors, rare diseases, and autoimmune disorders.

Eterna Therapeutics Inc. (Nasdaq: ERNA) presents at the ASGCT 27th Annual Meeting on the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features. The innovation aims to improve MSCs' therapeutic potential by addressing issues related to variability, in vivo persistence, and effector function. The presentation highlights the promising role of B2M-KO iMSCs in treating inflammatory diseases.